Systemic inflammation induced by exacerbation of COPD or pneumonia in patients with COPD induces cardiac troponin elevation

Vidar Søyseth,^{1,2} Natalia Kononova,^{3,4} Anke Neukamm,⁵ Nils Henrik Holmedahl,⁶ Tor-Arne Hagve,¹ Torbjørn Omland,^{2,7} Gunnar Einvik^{3,4}

To cite: Søyseth V, Kononova N, Neukamm A, *et al.* Systemic inflammation induced by exacerbation of COPD or pneumonia in patients with COPD induces cardiac troponin elevation. *BMJ Open Res* 2021;**8**:e000997. doi:10.1136/bmjresp-2021-000997

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjresp-2021-000997>).

Received 28 May 2021
Accepted 19 August 2021

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Medical Division, Akershus University Hospital, Lørenskog, Norway

²Campus Ahus, University of Oslo Faculty of Medicine, Lørenskog, Norway

³Institute for Clinical Medicine, University of Oslo, Oslo, Norway

⁴Division of Medicine, Akershus University Hospital, Lørenskog, Norway

⁵Department of Cardiology, Akershus University Hospital, Lørenskog, Norway

⁶Glittrelinikken, Hakadal, Norway

⁷Lørenskog, Norway

Correspondence to
Dr Vidar Søyseth;
vidar.soyseth@medisin.uio.no

ABSTRACT

Background Troponin is a biomarker of myocardial injury. In chronic obstructive pulmonary disease (COPD), troponin is an important determinant of mortality after acute exacerbation. Whether acute exacerbation of COPD (AECOPD) causes troponin elevation is not known. Here, we investigated whether troponin is increased in AECOPD compared to stable COPD.

Methods We included 320 patients with COPD in the stable state and 63 random individuals from Akershus University hospital's catchment area. All participants were ≥40 years old (mean 65.1 years, SD 7.6) and 176 (46%) were females. The geometric mean of high-sensitivity cardiac troponin T (hs-cTnT) was 6.9 ng/L (geometric-SD 2.6). They were followed regarding hospital admission for the subsequent 5 years.

Results During the 5-year follow-up, we noted 474 hospitalisations: Totally, 150 and 80 admissions were due to AECOPD or pneumonia, respectively. The geometric mean ratio with geometric SE (GSE) between cTnT at admission and stable state in AECOPD and pneumonia was 1.27 (GSE=1.11, p=0.023) and 1.28 (GSE=1.14, p=0.054), respectively. After inclusion of blood leucocyte count and C reactive protein at hospitalisation, these ratios attenuated to zero. However, we estimated an indirect of AECOPD and pneumonia on the ratio between hs-cTnT at admission and the stable state to 1.16 (p=0.022) and 1.22 (p=0.008), representing 91% (95% CI 82% to 100%) and 95% (95% CI 83% to 100%) of the total effects, respectively.

Conclusion AECOPD and pneumonia in patients with COPD is associated with higher cTnT levels. This association appears to be mediated by systemic inflammation.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterised by an irreversible limitation of airflow that is usually progressive.¹ A large proportion of patients experience periods with acute exacerbation of COPD symptoms (AECOPD) frequently triggered by airway infections and characterised by local airway and/or systemic inflammation.^{2,3} COPD is also accompanied by several

KEY MESSAGES

- ⇒ Cardiac troponin increases in chronic obstructive pulmonary disease (COPD) exacerbation.
- ⇒ Cardiac troponin is increased in exacerbation and pneumonia in COPD. This increase is mediated by systemic inflammation that accompanies exacerbation and pneumonia in COPD.
- ⇒ Airways inflammation triggers a systemic inflammation that damages the heart muscles.

comorbidities that may represent major health problems for patients. In particular, cardiovascular diseases are common and associated with increased mortality in patients with COPD.⁴⁻⁷ Previous studies have shown that a circulatory marker of myocardial damage, cardiac troponin (cTn), is an independent prognostic marker of mortality in the general population, in patients with stable COPD, and after AECOPD.⁸⁻¹⁰ The level of cTn has been shown to be inversely related to COPD severity as assessed by spirometry in the stable state.^{8,10-14} Moreover, the level of cTn has been reported to be higher in patients hospitalised for AECOPD than in patients with COPD in the stable state.^{15,16} However, prospective studies that examine the trajectory of cTn during the course of COPD are lacking, and whether myocardial damage, as indicated by cTn, progresses during an exacerbated state of COPD has not been determined. Furthermore, the mechanisms that may contribute to elevations in cTn have not been established. We conducted a longitudinal study of cTn in patients with COPD and healthy individuals for 5 years. As our laboratory uses the T-isomere of cTn, we chose T-isomere of cTn as our outcome parameter.

The primary aim of the present study was to test the hypothesis that the cTnT level increases during incident severe AECOPD

compared with stable COPD. We also aimed to assess the effect of other hospitalisations on the cTnT level and to elucidate possible mechanism(s) for any increase in cTnT.

MATERIAL AND METHODS

Study population and design

The study was conducted at Akershus University Hospital and Glitre Rehabilitation Hospital. The population consisted of five cohorts: (1) candidates for long-term oxygen therapy (LTOT), (2) patients with COPD participating in the rehabilitation course at the hospital's outpatient clinic, (3) institutional COPD rehabilitation patients, (4) patients with COPD referred to the hospital's outpatient clinic and (5) a presumably healthy reference group.^{17–19} All patients were in a stable state at inclusion, and none had AECOPD in the 6 weeks prior to inclusion. The reference group was selected by random sampling from the general population in the hospital's recruitment area. Seven of these 62 participants (11%) had irreversible airflow limitation, but none of them had their COPD diagnosed by a doctor.¹⁷

The LTOT candidates and the outpatient rehabilitation group were re-examined in the stable state 3 and 6 months after inclusion as a part of the routine programme, respectively. All participants were followed regarding acute hospitalisation until 5 years after inclusion. The main diagnosis at discharge was classified using the International Classification of Disease version 10. We included all diagnoses in order to compare changes in troponin between stable state and any cause of hospitalisation. All participants provided written consent.

Measurements

As our laboratory uses the T-isomere of cTn we chose T-isomere of cTn as our outcome parameter. High-sensitivity (hs)-cTnT at baseline was measured in venous serum samples stored at -80°C using a cobas e 411 immuno-analyser (Roche Diagnostics). The lower limit of detection was 3.0 ng/L. Using venous blood sampled at incident hospital admissions, hs-cTnT was analysed within 1 hour. Blood haemoglobin, blood leucocytes, serum C reactive protein (CRP) and serum creatinine were measured using routine laboratory methods. All of the blood samples were analysed at Akershus University Hospital's Clinical Biochemistry Laboratory.

At inclusion, spirometry was performed at the respiratory laboratories at Akershus University Hospital or Glitre Lung Rehabilitation Hospital as recommended by the European Respiratory Society/American Thoracic Society using the European Community for Coal and Steel reference equations.²⁰ A reversibility test was performed with 400 µg salbutamol unless the participant had inhaled a short-acting beta-2-stimulator or a short-acting muscarine receptor antagonist within 4 hours before spirometry.

Statistical analysis

Statistical analyses were performed in four levels. In the first level, we compared the baseline values of relevant variables in participants with incident hospitalisations to those of participants who were not hospitalised during the follow-up. Variables that were associated with hospitalisation with a corresponding $p < 0.2$ were retained for further analysis in addition to established determinants of cTnT, such as gender, arterial oxygen tension and creatinine. Next, in the second level, we performed a multivariable linear regression analysis of the baseline data with hs-cTnT as the dependent variable using ordinary least square regression. In this analysis, we log-transformed hs-cTnT at inclusion ($\ln_ctnt0$) because hs-cTnT was highly skewed to the right (online supplemental figure 1). Selected covariates were included using forward selection procedure. These covariates were added to the model, ordered by increasing numbers of missing values. In the final analysis of the baseline data, we invoked a model using multiple imputation.²¹

In the third level, we analysed the association between the level of hs-cTnT and the main diagnosis at each hospitalisation. The diagnoses were categorised into nine groups that were all inclusive and mutually exclusive. However, each participant could have several hospitalisations and different diagnoses during the follow-up. In these analyses, we invoked a multivariable model using log-transformed hs-cTnT ($\ln_ctnt$) at follow-up as the outcome variable and diagnosis group at hospitalisation, baseline covariates (including baseline hs-cTnT) and routine clinical data during follow-up as the explanatory variables.

In the fourth level, we investigated whether the relationship between hs-cTnT and diagnosis was mediated in the longitudinal analyses by any of the following clinical variables at hospitalisation: blood leucocytes, serum CRP, arterial oxygen-tension, serum creatinine or heart rate. For details, see online supplemental figure 2. We performed these analyses using a multivariable mixed model with multiple imputations for missing values.²¹ If the model did not converge, mixed model was replaced by ordinary least square regression with robust SEs. The time elapsed between inclusion and hospitalisation was also included as a covariate. Mediation of the relationship between diagnosis group and hs-cTnT by any of the clinical variables at follow-up was assessed in four steps: (1) The relationship between the potential mediator and diagnosis, adjusted for relevant covariates using a linear mixed model had to be significant (online supplemental equation 1). (2) The direct effect (θ_1) of diagnosis group on $\ln_ctnt$ (θ_1 , online supplemental equation 2) using all relevant covariates, including clinical follow-up data, as explanatory variables had to be non-significant. (3) After removal of the clinical covariates or combinations of the clinical follow-up variables from this model we estimated the

total effect of diagnosis group on $\ln_cntt$ (T1, online supplemental equation 3). Finally (4), we estimated the natural indirect effect (ie, the mediation effect) of diagnosis on hs-cTnT as the difference between T1 and θ_1 ($T1 - \theta_1$). The SEs, and thereby the p values, of these differences were estimated using bootstrapping.²² For details, see the online supplemental (mediation).

Continuous covariates were categorised in quartiles, and the analyses were performed using Stata V.16.1 (StataCorp).

RESULTS

Baseline analyses

Table 1 shows the baseline data for participants who were never hospitalised and those who were ever hospitalised during 5 years of follow-up. Totally, 30 and 23 patients were ever hospitalised for exacerbation or pneumonia, respectively. Among these patients, eight patients were hospitalised for exacerbation as well as pneumonia. We observed that individuals who were hospitalised during the follow-up were older, had higher baseline hs-cTnT, markedly lower spirometry results and higher cumulative

Table 1 Baseline characteristics of the total cohort at inclusion

Characteristics	Total	Ever hosp.	Never hosp.	P value
Sex, female, n (%)	175 (46)	83 (44)	92 (48)	0.434
Age, years, mean (SD)	65.1 (7.6)	67.0 (6.9)	63.5 (7.9)	<0.001
Laboratory data, mean (SD)				
Haemoglobin, g/dL	14.2 (1.3)	14.1 (1.4)	14.2 (1.3)	0.423
Leucocyte count, $10^9/L$	7.0 (2.2)	7.2 (2.4)	6.9 (2.0)	0.137
C reactive protein*, mg/L	2.6 (2.9)	3.0 (2.9)	2.2 (2.9)	0.006
Creatinine, mmol/L	75.5 (22.4)	76.6 (27.5)	74.5 (17.0)	0.352
hs-cTnT*, ng/L	6.9 (2.6)	8.8 (2.6)	5.6 (2.5)	<0.001
Clinical Variables, mean (SD)				
FVC, L	2.9 (1.3)	2.7 (1.4)	3.1 (1.1)	0.010
FEV1, L	1.6 (0.9)	1.4 (0.7)	1.8 (1.1)	<0.001
FVC of predicted, %	85.1 (28.1)	81.2 (34.1)	88.5 (21.4)	0.012
FEV1 of predicted, %	56.5 (27.4)	50.1 (24.0)	61.8 (29.0)	<0.001
Arterial O ₂ -tension, kPa	9.3 (1.7)	9.2 (1.6)	9.4 (1.8)	0.335
Arterial CO ₂ -tension, kPa	5.3 (0.8)	5.3 (0.8)	5.4 (0.8)	0.316
Systolic BP, mm Hg	134.1 (21.3)	134.6 (20.9)	133.6 (21.6)	0.670
Heart rate (ECG), 1/min	71.8 (12.9)	73.0 (13.6)	70.7 (12.1)	0.113
Q-wave ECG, n (%)	26 (8)	17 (11)	9 (6)	0.109
Clinical History, n (%)				
Coronary arterial disease	23 (6)	16 (9)	7 (3)	0.018
Arterial hypertension	155 (40)	78 (45)	77 (37)	0.134
Diabetes mellitus	24 (6)	13 (7)	11 (5)	0.389
Smoking habits				
Current smoking, n (%)	103 (27)	43 (25)	60 (29)	0.365
Former smoking, n (%)	244 (64)	125 (72)	119 (53)	0.003
Pack-years, mean (SD)	33.1 (21.0)	37.9 (20.3)	29.1 (20.8)	<0.001
Group				<0.001
References	63 (16)	12 (7)	51 (25)	
LTOT candidates	21 (5)	16 (9)	5 (2)	
Rehabilitation group				
Outpatients	63 (16)	47 (28)	16 (8)	
Institutional	63 (16)	13 (7)	50 (24)	
Unselected outpatients	173 (45)	87 (50)	86 (41)	

BP, Blood Pressure; CRP, C-Reactive Protein; FEV1, forced expiratory volume in 1 s; FEV1, Forced Expiratory Volume in one second; FVC, Forced Volume Capacity; Hosp, hospitalised; hs-cTnT, high-sensitivity cardiac troponin T; LTOT, long-term oxygen therapy.

tobacco consumption than those who were never hospitalised. However, the prevalence of current smoking was not different between these two groups (table 1). Finally, the proportion of participants having incident hospitalisation during the follow-up was significantly different between the cohorts.

The univariable analyses of associations between hs-cTnT and covariates at baseline are shown in online supplemental table 1A,B. These analyses show that hs-cTnT was higher in males, patients with pathological Q-waves on the ECG, and participants with arterial hypertension than in their respective counterparts. However, hs-cTnT was lower in current smokers than current non-smokers. Similarly, the univariate ordinary least square regression analyses of hs-cTnT (expressed as $\ln_cntnt0$) as the outcome and continuous covariate (in quartiles) showed a positive association with age, peripheral leucocyte count, CRP, creatinine and heart rate (online supplemental table 1B). Similarly, we identified a significant inverse relationship between hs-cTnT and spirometry variables, and with arterial oxygen tension.

Three participants were excluded from the analyses because they had missing values for forced expiratory volume in 1 s, blood leucocytes or smoking at baseline. Therefore, the analyses were restricted to the remaining 380 participants. All of these individuals had complete data regarding cohort group, gender, age, peripheral leucocytes, creatinine, spirometry, history of arterial hypertension, coronary heart disease and smoking status. The baseline data were incomplete regarding ECG ($n=70$), arterial oxygen tension ($n=75$) and serum CRP ($n=27$; online supplemental table 2).

The results of the multivariable analysis of the baseline data with $\ln_cntnt0$ as the dependent variable by increasing the number of covariates without missing values as explanatory variables in ordinary least square regression are

shown in table 2. After inclusion of pathological Q-wave as a covariate, the number of individuals available for analysis was reduced to 310 participants (82%). At this step, we observed that the hs-cTnT level was higher in the COPD groups than the reference group. After inclusion of the remaining continuous covariates, the number of participants available for analysis was reduced to 270 individuals (71% of the total sample). Interestingly, after these adjustments, hs-cTnT was not higher in any of the patient groups than the reference group. After application of multiple imputations, the SEs were generally smaller than in the full model without imputations. The coefficients were mainly unchanged but, without imputations, the programme failed to estimate the coefficient for the LTOT candidates.

Longitudinal analyses

The diagnoses, number of hospitalisations, number of hs-cTnT measurements and corresponding geometric mean and geometric SD (GSD) of hs-cTnT at baseline and hospitalisation by diagnosis group are summarised in table 3. The hs-cTnT measurements were available in 353 (74%) of hospitalisations. The fraction of hs-cTnT measurements was $\geq 85\%$ in AECOPD, pneumonia, non-respiratory infections and diseases in the circulatory system. The overall geometric mean of hs-cTnT (corresponding GSD) at hospitalisation was 10.6 (2.5) ng/L (table 3). A detailed text version of the diagnoses is found in online supplemental table 3.

Analysis of the association between hs-cTnT and diagnosis at incident hospitalisations adjusted for follow-up time showed that hs-cTnT was significantly higher during the hospitalisation in AECOPD, pneumonia, 'other lung diseases', non-respiratory infections, circulatory diseases and 'other diagnoses' compared with the stable state

Table 2 Hs-cTnT measures at baseline and hospitalisation by diagnosis

Diagnosis at hospital admittance	N	n	n/N, %	hs-cTnT: admittance		hs-cTnT: baseline		Ratio
				GM	GSD	GM	GSD	
COPD exacerbation	150	140	93	19.7	2.1	12.6	2.4	1.6
Pneumonia	80	67	84	20.5	2.5	13.5	2.6	1.5
Other lung diseases	43	21	49	15.5	2.7	10.4	2.5	1.5
Non-respiratory infections	6	6	100	25.4	3.3	9.0	3.5	2.8
Circulatory diseases	52	48	92	15.5	2.7	9.5	1.9	1.6
Cancer	21	9	45	20.0	2.3	8.3	1.8	2.4
Digestive diseases	26	11	41	13.3	2.2	8.2	3.1	1.6
Symptom diagnoses	30	24	80	8.2	1.6	7.2	2.3	1.1
Other diagnoses	65	26	39	21.5	2.5	8.3	2.7	2.6
Total	473	352	74	10.6	2.5	7.1	2.6	1.5

Regarding ICD-10 diagnoses are given in online supplemental table 3.

COPD, chronic obstructive pulmonary disease; GM, geometric mean; GSD, geometric SD; hs-cTnT, high-sensitivity cardiac troponin T; ICD-10, International Classification of Disease version 10.

Table 3 Ratio between the level of high-sensitive cardiac troponin T in four different models

	Model 1			Model 2			Model 3: total effects			Model 4: direct effects		
	Ratio	GSE	P value	Ratio	GSE	P value	Ratio	GSE	P value	Ratio	GSE	P value
Diagnosis												
AECOPD	1.47	1.10	<0.001	1.40	1.10	<0.001	1.27	1.11	0.023	1.08	1.12	0.513
Pneumonia	1.59	1.11	<0.001	1.53	1.11	<0.001	1.28	1.14	0.054	1.01	1.15	0.929
Other lung diseases	1.40	1.19	0.047	1.31	1.18	0.107	1.06	1.24	0.775	0.96	1.24	0.839
Non-respiratory infection	2.23	1.32	0.004	2.29	1.32	0.003	2.45	1.36	0.003	1.79	1.36	0.061
Circulatory diseases	2.78	1.14	<0.001	2.71	1.13	<0.001	2.12	1.18	<0.001	1.98	1.18	<0.001
Cancer	1.40	1.27	0.154	1.37	1.26	0.177	0.89	1.42	0.745	0.73	1.42	0.370
Digestive diseases	1.21	1.28	0.442	1.21	1.27	0.438	1.45	1.27	0.123	1.32	1.27	0.242
Symptom diagnoses	1.13	1.17	0.442	1.13	1.17	0.435	1.22	1.22	0.327	1.12	1.22	0.578
Other diagnoses	1.59	1.16	0.002	1.56	1.16	0.003	1.40	1.41	0.326	1.22	1.41	0.556
Follow-up time in years	1.13	1.03	<0.001	1.12	1.03	<0.001	1.11	1.04	0.004	1.12	1.04	0.004
Baseline covariates												
Study group vs references												
LTOT candidates				1.31	1.26	0.246	Omitted					
Institutional				0.96	1.19	0.836	Omitted					
Outpatients				0.82	1.18	0.232	0.81	1.11	0.039			
Outpatient clinic				0.53	1.21	0.001	Omitted					
Covariates, baseline												
Sex: female versus male				0.63	1.09	<0.001	1.00	1.09	0.978			
Age in quartiles				1.12	1.04	0.002	1.02	1.04	0.521			
Pack-years in quartiles				0.98	1.04	0.542	0.94	1.03	0.071			
Hypertension: Y vs N				1.24	1.08	0.009	0.94	1.08	0.420			
Coronary artery disease: Y vs N				1.10	1.18	0.576	1.19	1.29	0.491			
Q-wave ECG: Y vs N				1.04	1.16	0.783	1.01	1.14	0.962			
Continuous baseline covariates in quartile												
Creatinine				1.14	1.04	0.002	1.02	1.04	0.522			
Leucocytes				1.07	1.04	0.072	1.07	1.04	0.056			
C reactive protein				1.02	1.04	0.615	1.04	1.03	0.199			
FEV1				0.78	1.05	<0.001	0.99	1.04	0.729			
Arterial O ₂ -tension				0.89	1.05	0.018	0.94	1.04	0.114			
High-sensitive cardiac troponin T							1.93	1.04	<0.001	1.87	1.03	<0.001

Continued

Table 3 Continued

	Model 1			Model 2			Model 3: total effects			Model 4: direct effects		
	Ratio	GSE	P value	Ratio	GSE	P value	Ratio	GSE	P value	Ratio	GSE	P value
Biomarkers during follow-up in quartiles												
Leucocytes										1.09	1.04	0.015
C reactive protein										1.08	1.04	0.038
Creatinine										1.06	1.03	0.052
Arterial O ₂ -tension										1.01	1.03	0.823
Heart rate										1.08	1.03	0.028
AECOPD, acute exacerbation of chronic obstructive pulmonary disease; FEV ₁ , forced expiratory volume in 1 s; GSE, geometric SE; LTOT, long-term oxygen treatment;.												

(table 4, model 1). After adjusting for determinants of baseline hs-cTnT, the associations between hs-cTnT at follow-up and diagnoses was slightly attenuated for most of the diagnosis group (table 4, model 2). When we included baseline hs-cTnT as a covariate, the relationships between diagnosis group and hs-cTnT, that is, the total effect, attenuated substantially more and was no longer significant regarding 'other diagnoses' (table 4, model 3). The relationship between hs-cTnT and AECOPD remained significant, but the association with pneumonia was not significant ($p=0.054$). Moreover, in model 3, the association between hs-cTnT at hospital admission and baseline covariates were no longer significant. Thus, baseline determinants of hs-cTnT were removed from the model, resulting in a more parsimonious model with fewer imputations (online supplemental table 5, full model).

In the next step, we added blood leucocytes, serum CRP, serum creatinine, arterial O₂-tension and heart rate at hospital admission to the model. The association between all diagnoses, except circulatory diseases, and hs-cTnT (ie, the direct effect) at admission attenuated to zero (table 4, model 4). Furthermore, the relationships between hs-cTnT and leucocytes, CRP and heart rate, but not arterial O₂-tension, at admission were significant. Therefore, we investigated the relationship between leucocytes, CRP and heart rate at admission as outcome variables and diagnoses, observation time, baseline hs-cTnT and covariates at hospitalisation as explanatory covariates in separate linear mixed models. A linear mixed model with heart rate as the outcome variable did not converge, even when we log-transformed heart rate. Therefore, in the analysis of heart rate, we replaced the linear mixed model with ordinary least square regression and robust SEs. In these analyses, both leucocytes and CRP were positively related to AECOPD, pneumonia, non-respiratory infections and circulatory diseases, whereas the association between heart rate and diagnoses was not significant (online supplemental table 4).

Finally, we estimated the indirect effect of AECOPD, pneumonia and non-respiratory infection on hs-cTnT as the difference between the total effect and the direct effect: $IE=T1 - \theta1$. SEs were obtained by bootstrapping the difference using 100 replications (online supplemental table 5). Leucocytes and CRP jointly had a significant effect on the ratio between hs-cTnT at hospital admission and hs-cTnT in the stable state, that is, mediated the effect of AECOPD, pneumonia and non-respiratory infections on hs-cTnT. It is likely that this joint effect of CRP and leucocytes is indirect, that is, mediated by some factor(s) that we did not have information about. The joint effects of leucocytes and CRP on the indirect effect of AECOPD and pneumonia on hs-cTnT represented 91% (95% CI 82% to 100%) and 95% (95% CI 83% to 100%) of the total effects, respectively. The corresponding results for non-respiratory infections was 51% (95% CI 36% to 74%). As leucocytes were highly significantly related to circulatory diseases, we also estimated the indirect effect

Table 4 The natural indirect effect of AECOPD, pneumonia and non-respiratory infections on the ratio of high-sensitivity cardiac troponin T at admission versus stable state with corresponding GSE and p values mediated by peripheral leucocytes and CRP per quartile

	AECOPD			Pneumonia			Non-respiratory infections		
	Ratio	GSE	P value	Ratio	GSE	P value	Ratio	GSE	P value
Leucocytes	1.07	1.04	0.082	1.06	1.04	0.183	1.13	1.07	0.053
CRP	1.05	1.03	0.096	1.11	1.06	0.080	1.07	1.04	0.061
Leucocytes or CRP	1.16	1.07	0.022	1.22	1.08	0.008	1.26	1.12	0.043

AECOPD, acute exacerbation of chronic obstructive pulmonary disease; CRP, C reactive protein; GSE, geometric SE.

of leucocytes by circulatory diseases. This indirect effect was not significant ($p=0.125$).

Discussion

In this study, we found that AECOPD and pneumonia may elevate cTnT indirectly by increasing systemic inflammation. We also found the same effect for non-respiratory infections.

To the best of our knowledge, a positive association between indices of systemic inflammation that is induced by AECOPD or pneumonia, that is, airways inflammation, and myocardial injury has not been described before.

The main strength of this study is that patients were enrolled in stable state, and that diagnoses at hospital admission were made without any knowledge about their state at inclusion. Moreover, in the majority of the patients hospitalised for exacerbation and pneumonia measurements of troponin was available.

Because the association between AECOPD and pneumonia with hs-cTnT attenuated substantially after inclusion of leucocytes and CRP as covariates, one may wonder whether leucocytes and CRP should be regarded as confounders of the relationship between AECOPD and cTnT. However, we think a causal relationship exists between AECOPD and the increase in leucocytes and CRP. Therefore, leucocytes and CRP should be regarded as mediators, not as confounders, of the relationship between AECOPD and troponin elevation.^{23 24} We think these considerations also encompass pneumonia insofar as the total effect of pneumonia on cTnT elevation was the same as that of AECOPD. The p value for pneumonia was lower than the p value for AECOPD mostly because of fewer pneumonia events relative to AECOPD. Moreover, the distinction between pneumonia and AECOPD in patients with COPD is not clear.

As the increase in leucocytes in AECOPD and pneumonia reflects an effect of airway inflammation on the bone marrow, and the increase in CRP is caused by cytokines produced by circulating granulocytes, we regard the joint effect of leucocytes and CRP in these events as a systemic effect of AECOPD and pneumonia. Furthermore, systemic inflammation may increase cTn, particularly in severe infections.²⁵ This is in agreement with our findings regarding non-respiratory infections. On the other hand, circulatory diseases were weakly associated

with leucocytes and CRP, and the cTnT level in this group was nearly unchanged after inclusion of leucocytes and CRP as covariates. Thus, the cTnT elevation was likely a direct consequence of myocardial disease.

The clinical implication of our finding is that reduction of systemic inflammation be given more focus in the treatment of COPD.

Heart rate was also positively associated with troponin elevation, but not with AECOPD or pneumonia, and removal did not change the relationship between AECOPD or pneumonia and troponin. Thus, the confounding effect of heart rate was negligible and it was not a mediator the relationship between AECOPD or pneumonia and troponin.

We also noted that we did not find any association between troponin and hypoxaemia. This is in agreement with two other previous cohorts.^{26 27} As in our previous studies, we did not have information on oxygen tension in the patients prior to admission. Moreover, it could also be explained by insufficient number of patient. Therefore, we cannot exclude hypoxaemia as a putative contributor of troponin elevation at admission.

Several studies have reported that troponin elevation is associated with the severity of stable COPD and that troponin elevation is associated with an unfavourable prognosis after COPD exacerbation and in the stable state.²⁸ The relationship between AECOPD and increased troponin has been less studied. In a cohort of 98 stable patients with COPD who were followed over several months, 55 patients were investigated in both their stable state and during exacerbation.²⁹ Among these patients, 24 who had verified an infectious cause of the exacerbation had troponin elevation during the exacerbation. This elevation was most pronounced in patients with concomitant coronary artery disease. In another study, a minority of patients referred to hospital due to AECOPD had elevated cTnT that normalised within 72 hours of admission.³⁰ However, in the latter study, they had not determined cTnT values in the stable state prior to hospitalisation. Therefore, they could not adjust for cTnT in the stable state prior to admission.

The main limitation of this study was that we did not re-examine the individuals who were not hospitalised during the follow-up, except the LTOT candidates and members of the outpatient rehabilitation group.

Therefore, data about the natural course of cTnT in the cohort were sparse. However, this limitation should not distort the results, as we adjusted for follow-up time in the analyses.

In conclusion, systemic inflammation in COPD caused by exacerbation or pneumonia mediates elevation of cTnT.

Acknowledgements The authors would like to thank the individuals who participated in this study. We also wish to thank Annika Lorentzen, Vigdis Bakkelund, and Hege Kristin Netmangen Larsen of the Department of Research, Division of Medicine, and Akershus University Hospital, for their assistance with the clinical and laboratory procedures.

Contributors VS: design, data management, analyses, main author; NK: data collection, manuscript preparation; AN: data collection, manuscript preparation; NHH: data collection, manuscript preparation; T-AH: laboratory services, manuscript preparation; TO: design manuscript preparation; GE: design, manuscript preparation.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests TO has served on advisory boards for Abbott Diagnostics, Roche Diagnostics and Bayer and has received research support from Abbott Diagnostics, Novartis, Roche Diagnostics, Singulex and SomaLogic via Akershus University Hospital, and speaker's or consulting honoraria from Roche Diagnostics, Siemens Healthineers and CardiNor, otherwise: none to declare.

Patient consent for publication Not required.

Ethics approval The study was approved by the Regional Ethics committee.

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement Data are available on reasonable request. Data are available upon request to the first author.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- Celli BR, Decramer M, Wedzicha JA, *et al.* An official American thoracic Society/European respiratory Society statement: research questions in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015;191:e4–27.
- Rohde G, Borg I, Wiethage A, *et al.* Inflammatory response in acute viral exacerbations of COPD. *Infection* 2008;36:427–33.
- Sethi S, Mahler DA, Marcus P, *et al.* Inflammation in COPD: implications for management. *Am J Med* 2012;125:1162–70.
- Chen W, Thomas J, Sadatsafavi M, *et al.* Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Lancet Respir Med* 2015;3:631–9.
- Divo M, Cote C, de Torres JP, *et al.* Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012;186:155–61.
- Feary JR, Rodrigues LC, Smith CJ, *et al.* Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. *Thorax* 2010;65:956–62.
- Müllerova H, Agusti A, Erqou S, *et al.* Cardiovascular comorbidity in COPD: systematic literature review. *Chest* 2013;144:1163–78.
- Adamson PD, Anderson JA, Brook RD, *et al.* Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. *J Am Coll Cardiol* 2018;72:1126–37.
- de Lemos JA, Drazner MH, Omland T, *et al.* Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. *JAMA* 2010;304:2503–12.
- Høise AD, Neukamm A, Karlsson BD, *et al.* Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. *Thorax* 2011;66:775–81.
- Baum C, Ojeda FM, Wild PS, *et al.* Subclinical impairment of lung function is related to mild cardiac dysfunction and manifest heart failure in the general population. *Int J Cardiol* 2016;218:298–304.
- de Lemos JA, deFilippi CR. Prevalence and significance of detectable troponins as measured by highly sensitive assays in the general population. *Coron Artery Dis* 2013;24:705–9.
- Olson F, Engborg J, Grønhoj MH, *et al.* Association between high-sensitive troponin I and coronary artery calcification in a Danish general population. *Atherosclerosis* 2016;245:88–93.
- Omland T, de Lemos JA, Holmen OL, *et al.* Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. *Clin Chem* 2015;61:646–56.
- Campo G, Pavasini R, Malagù M, *et al.* Relationship between troponin elevation, cardiovascular history and adverse events in patients with acute exacerbation of COPD. *COPD* 2015;12:560–7.
- Søyseth V, Bhatnagar R, Holmedahl NH, *et al.* Acute exacerbation of COPD is associated with fourfold elevation of cardiac troponin T. *Heart* 2013;99:122–6.
- Kononova N, Sikkeland LIB, Mahmood F, *et al.* Annual decline in forced expiratory volume and airway inflammatory cells and mediators in a general population-based sample. *BMC Pulm Med* 2019;19:90.
- Neukamm A, Einvik G, Didrik Høise AD, Didrik HA, *et al.* The prognostic value of measurement of high-sensitive cardiac troponin T for mortality in a cohort of stable chronic obstructive pulmonary disease patients. *BMC Pulm Med* 2016;16:164.
- Neukamm AMC, Høise AD, Hagve T-A, *et al.* High-Sensitivity cardiac troponin T levels are increased in stable COPD. *Heart* 2013;99:382–7.
- Miller MR, Hankinson J, Brusasco V, *et al.* Standardisation of spirometry. *Eur Respir J* 2005;26:319–38.
- Royston P. Multiple imputation of missing values. *Stata J* 2004;4:227–41.
- Royston P, Sauerbrei W. Bootstrap assessment of the stability of multivariable models. *Stata J* 2009;9:547–70.
- Corraini P, Olsen M, Pedersen L, *et al.* Effect modification, interaction and mediation: an overview of theoretical insights for clinical Investigators. *Clin Epidemiol* 2017;9:331–8.
- VanderWeele TJ. Bias formulas for sensitivity analysis for direct and indirect effects. *Epidemiology* 2010;21:540–51.
- Agewall S, Giannitsis E, Jernberg T, *et al.* Troponin elevation in coronary vs. Non-Coronary Disease. *Eur Heart J* 2011;32:404–11.
- Brekke PH, Omland T, Holmedahl SH, *et al.* Determinants of cardiac troponin T elevation in COPD exacerbation - a cross-sectional study. *BMC Pulm Med* 2009;9:35.
- Høise AD, Omland T, Hagve T-A, *et al.* Determinants of high-sensitivity cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. *BMC Pulm Med* 2012;12:22.
- Pavasini R, d'Ascenzo F, Campo G, *et al.* Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: systematic review and meta-analysis. *Int J Cardiol* 2015;191:187–93.
- Patel ARC, Kowlessar BS, Donaldson GC, *et al.* Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013;188:1091–9.
- Shafuddin E, Chang CL, Cooray M, *et al.* Changes in biomarkers of cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. *Respir Med* 2018;145:192–9.